• Source: Aztreonam/avibactam

Aztreonam/avibactam, sold under the brand name Emblaveo (by Pfizer), is a combination of aztreonam, a β-lactam antibiotic, and avibactam, a β-Lactamase inhibitor, developed by AbbVie and Pfizer for aerobic Gram-negative infections. Drug resistance to the combination has been reported.
The combination was approved for medical use in the European Union in April 2024.




Medical uses


Aztreonam/avibactam is indicated for the treatment of complicated intra-abdominal infection; hospital-acquired pneumonia, including ventilator-associated pneumonia; or complicated urinary tract infection, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.




Society and culture






= Legal status

=
In March 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Emblaveo, intended for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia and infections due to aerobic Gram-negative organisms in people with limited treatment options. The applicant for this medicinal product is Pfizer Europe MA EEIG. The combination was approved for medical use in the European Union in April 2024.




References

Kata Kunci Pencarian:

• Aztreonam
• Avibaktam
• Aztreonam
• Aztreonam/avibactam
• Avibactam
• Ceftazidime/avibactam
• List of drugs: As–Az
• List of β-lactam antibiotics
• Multiple drug resistance
• Beta-lactamase
• Benzathine benzylpenicillin
• List of antibiotics